130 related articles for article (PubMed ID: 14976916)
1. [Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia].
Gerstein ES; Gritsaenko EV; Shcherbakov ME; Shcherbakov AM; Ognerudov NA; Kushlinskiĭ NE
Vopr Onkol; 2003; 49(6):725-9. PubMed ID: 14976916
[TBL] [Abstract][Full Text] [Related]
2. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
[TBL] [Abstract][Full Text] [Related]
3. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma.
Köhler U; Hiller K; Martin R; Langanke D; Naumann G; Bilek K; Jänicke F; Schmitt M
Gynecol Oncol; 1997 Aug; 66(2):268-74. PubMed ID: 9264575
[TBL] [Abstract][Full Text] [Related]
5. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
6. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients.
Abendstein B; Daxenbichler G; Windbichler G; Zeimet AG; Geurts A; Sweep F; Marth C
Anticancer Res; 2000; 20(1B):569-72. PubMed ID: 10769727
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
Osmak M; Babić D; Abramić M; Milicić D; Vrhovec I; Skrk J
Neoplasma; 2001; 48(6):462-7. PubMed ID: 11949838
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; van Schaik JH; Boonstra H; Sweep CG
Anticancer Res; 2002; 22(1A):275-82. PubMed ID: 12017303
[TBL] [Abstract][Full Text] [Related]
11. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
12. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
13. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
14. [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer].
Gerstein ES; Shcherbakov AM; Kaz'min AI; Ognerubov NA; Kushlinskiĭ NE
Vopr Onkol; 2003; 49(2):165-9. PubMed ID: 12785198
[TBL] [Abstract][Full Text] [Related]
15. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer.
Vidal O; Metges JP; Elizalde I; Valentíni M; Volant A; Molina R; Castells A; Pera M
Br J Surg; 2009 Dec; 96(12):1443-51. PubMed ID: 19918848
[TBL] [Abstract][Full Text] [Related]
16. A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study.
Dariusz S; Agnieszka M; Elzbieta R; Danuta ON; Maciej Z; Piotr D; Nowicki M
Eur J Obstet Gynecol Reprod Biol; 2012 Aug; 163(2):193-9. PubMed ID: 22525297
[TBL] [Abstract][Full Text] [Related]
17. CSF levels of growth factors and plasminogen activators in leptomeningeal metastases.
van de Langerijt B; Gijtenbeek JM; de Reus HP; Sweep FC; Geurts-Moespot A; Hendriks JC; Kappelle AC; Verbeek MM
Neurology; 2006 Jul; 67(1):114-9. PubMed ID: 16832089
[TBL] [Abstract][Full Text] [Related]
18. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
[TBL] [Abstract][Full Text] [Related]
19. Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms.
Lindholt JS; Jørgensen B; Shi GP; Henneberg EW
Eur J Vasc Endovasc Surg; 2003 Jun; 25(6):546-51. PubMed ID: 12787697
[TBL] [Abstract][Full Text] [Related]
20. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
